CHENGDU, China, June 3, 2011 /PRNewswire-Asia-FirstCall/ —
Tianyin Pharmaceutical Co., Inc. (NYSE Amex:
TPI), a pharmaceutical company that specializes in patented
biopharmaceutical medicine, modernized traditional Chinese
medicine, branded generics and other pharmaceuticals today
announced that the Board of Directors has reinstated the stock
repurchase program that authorized the repurchase of up to 3
million TPI’s common stock on the open market at prevailing market
“The stock repurchase program illustrates our confidence in the
long-term growth of the Company and our commitment to returning
capital to our shareholders,” said Dr. Jiang, Guoqing, Chairman and
CEO of TPI.
TPI will update investors on the status of the repurchase
program on a quarterly basis, in conjunction with the reporting of
its quarterly and annual financial results.
About TPIHeadquartered at Chengdu, China, TPI is a
pharmaceutical company that specializes in the development,
manufacturing, marketing and sales of patented biopharmaceutical,
modernized traditional Chinese medicines, branded generics and
other pharmaceuticals. TPI currently manufactures a comprehensive
portfolio of 58 products, 24 of which are listed in the highly
selective national medicine reimbursement list, 7 are included in
the essential drug list of China. TPI’s pipeline targets various
high incidence healthcare indications. TPI has an extensive
nationwide distribution network with a sales force of 730 sales
representatives out of totaled 1,365 employees.
For more information about TPI, please visit: http://www.tianyinpharma.com.
Safe Harbor StatementThe Statements which are not historical
facts contained in this press release are forward-looking
statements that involve certain risks and uncertainties including
but not limited to risks associa